MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-12825

  1. 17,010 Posts.
    lightbulb Created with Sketch. 2412
    But Remestemcel failed to show any improvement in cardiac performance. In what way do you think it would have a role in this indication?

    And... No successful RCT, no approval. A trend worthy of further investigation. Do a proper trial to show efficacy exists or not. Previously it was claimed that it helped improve CHF. Then the next trial couldn't replicate the result...
    Last edited by whytee: 02/03/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.